COM:CEREVEL
Cerevel Therapeutics
- Stock
Last Close
44.63
31/07 20:00
Market Cap
7.46B
Beta: -
Volume Today
15.03M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Aug '14 | Aug '15 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | 52K - | 42K 19.23% | -364.50K - | -1.39M 280.66% | -1.02M 26.27% | |||
average payables | 4.05M - | 4.34M 7.12% | 3.55M - | 8.15M 129.39% | 10.68M 31.11% | 10.96M 2.65% | ||
average receivables | 663.50K - | 473.50K 28.64% | 364.50K - | 1.39M 280.66% | 1.02M 26.27% | |||
book value per share | 1.94 - | 0.30 84.74% | 0.61 106.90% | 5.22 752.92% | 4.24 18.85% | 3.45 18.68% | 0.00 99.88% | |
capex per share | -0.07 - | -0.03 61.83% | -0.01 68.19% | -0.26 2,867.40% | -0.08 70.02% | -0.03 66.01% | -0.00 99.91% | |
capex to depreciation | -0.67 - | -0.59 11.88% | -6.21 954.09% | -47.59 666.41% | -3.85 91.92% | -0.81 79.03% | 0.27 133.55% | |
capex to operating cash flow | 0.04 - | 0.02 62.91% | 0.02 6.77% | 0.16 931.98% | 0.06 63.32% | 0.01 77.07% | 0.01 17.51% | |
capex to revenue | -0.42 - | -0.14 66.27% | ||||||
cash per share | 1.97 - | 0.57 71.09% | 0.63 10.07% | 5.21 732.44% | 4.14 20.49% | 5.90 42.38% | 0.01 99.90% | |
days of inventory on hand | 10.15 - | |||||||
days payables outstanding | 516.87 - | 305.06 40.98% | ||||||
days sales outstanding | 56.18 - | 77.43 37.83% | ||||||
debt to assets | 1.38 - | 3.25 134.86% | 0.24 92.76% | 0.07 68.48% | 0.05 28.43% | 0.36 584.45% | 0.30 18.35% | |
debt to equity | 0.15 - | 1.04 574.32% | 0.37 65.06% | 0.09 76.49% | 0.06 26.43% | 0.71 1,022.76% | 0.55 22.84% | |
dividend yield | ||||||||
earnings yield | -0.17 - | -0.17 3.97% | -0.08 48.93% | -0.12 46.82% | -0.05 59.68% | -0.07 46.66% | -0.00 99.91% | |
enterprise value | 166.10M - | 165.75M 0.22% | 1.46B 781.85% | 870.38M 40.45% | 4.27B 390.74% | 5.00B 17.08% | 6.87T 137,293.50% | |
enterprise value over ebitda | -5.99 - | -6.03 0.75% | -39.67 557.48% | -5.84 85.29% | -19.41 232.48% | -13.60 29.94% | -15.36K 112,897.71% | |
ev to operating cash flow | -7.36 - | -7.14 3.03% | -20.67 189.51% | -7.39 64.25% | -23.92 223.78% | -17.06 28.70% | -20.07K 117,580.02% | |
ev to sales | 69.10 - | 60.94 11.81% | ||||||
free cash flow per share | -1.66 - | -1.66 0.11% | -0.56 65.92% | -1.86 228.55% | -1.38 25.43% | -1.96 41.91% | -0.00 99.89% | |
free cash flow yield | -0.14 - | -0.14 0.11% | -0.05 65.92% | -0.11 135.81% | -0.04 61.86% | -0.06 45.87% | -0.00 99.92% | |
graham net net | 1.65 - | 0.11 93.11% | 0.29 153.02% | 4.38 1,424.13% | 3.34 23.90% | 2.62 21.54% | 0.00 99.90% | |
graham number | 9.48 - | 3.63 61.72% | 3.73 2.80% | 15.58 317.70% | 12.46 20.01% | 13.42 7.71% | 0.02 99.88% | |
income quality | 0.77 - | 0.82 7.16% | 0.55 33.20% | 0.77 40.57% | 0.79 2.33% | 0.83 5.26% | 0.79 5.19% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -430.25 - | -939.23 118.30% | -38.24 - | 42.33 210.68% | ||||
interest debt per share | 0.31 - | 0.31 1.98% | 0.22 28.20% | 0.45 100.53% | 0.27 40.29% | 2.51 836.79% | 0.00 99.91% | |
inventory turnover | 35.96 - | |||||||
invested capital | 0.15 - | 1.04 574.32% | 0.37 65.06% | 0.09 76.49% | 0.06 26.43% | 0.71 1,022.76% | 0.55 22.84% | |
market cap | 169.44M - | 169.44M 0% | 1.51B 792.81% | 1.22B 19.29% | 4.43B 262.64% | 4.77B 7.75% | 6.87T 143,922.42% | |
net current asset value | 24.51M - | 2.86M 88.35% | 44.09M 1,443.37% | 329.81M 647.96% | 467.83M 41.85% | 409.07M 12.56% | 437.38M 6.92% | |
net debt to ebitda | 0.12 - | 0.13 11.81% | 1.39 932.46% | 2.35 69.40% | 0.71 69.77% | -0.63 188.01% | 0.11 117.10% | |
net income per share | -2.06 - | -1.98 3.97% | -1.01 48.93% | -2.07 104.56% | -1.63 21.16% | -2.32 42.68% | -0.00 99.89% | |
operating cash flow per share | -1.58 - | -1.63 2.90% | -0.56 65.88% | -1.60 187.55% | -1.31 18.28% | -1.94 48.26% | -0.00 99.89% | |
payables turnover | 0.71 - | 1.20 69.44% | ||||||
receivables turnover | 6.50 - | 4.71 27.45% | ||||||
research and ddevelopement to revenue | 5.89 - | 3.56 39.54% | ||||||
return on tangible assets | -9.47 - | -20.76 119.18% | -1.06 94.88% | -0.34 67.85% | -0.32 5.50% | -0.35 6.96% | -0.35 0.81% | |
revenue per share | 0.17 - | 0.19 13.14% | ||||||
roe | -1.06 - | -6.68 529.29% | -1.65 75.31% | -0.40 76.02% | -0.38 2.86% | -0.67 75.45% | -0.64 4.74% | |
roic | -0.92 - | -3.27 256.47% | -0.62 81.04% | -0.33 46.63% | -0.33 0.73% | -0.40 19.74% | -0.42 4.26% | |
sales general and administrative to revenue | 6.02 - | 5.86 2.70% | ||||||
shareholders equity per share | 1.94 - | 0.30 84.74% | 0.61 106.90% | 5.22 752.92% | 4.24 18.85% | 3.45 18.68% | 0.00 99.88% | |
stock based compensation to revenue | 1.28 - | 0.83 34.75% | ||||||
tangible asset value | -1.72M - | -5.55M 222.85% | 77.82M 1,501.46% | 384.52M 394.10% | 578.73M 50.51% | 521.24M 9.93% | 673.75M 29.26% | |
tangible book value per share | -0.12 - | -0.39 222.85% | 0.61 256.97% | 5.22 752.92% | 4.24 18.85% | 3.45 18.68% | 0.00 99.88% | |
working capital | 24.61M - | 4.54M 81.53% | 72.20M 1,488.93% | 361.01M 400.01% | 535.48M 48.33% | 833.09M 55.58% | 914.76M 9.80% |
All numbers in (except ratios and percentages)